Oppenheimer Downgrades Bio-Reference Laboratories (BRLI) to Perform

January 9, 2009 9:48 AM EST

Oppenheimer downgrades Bio-Reference Laboratories (Nasdaq: BRLI) from Outperform to Perform. Price target $25.

Bio-Reference Laboratories, Inc. is an independent regional clinical laboratory servicing the greater New York metropolitan area.


Related Categories

Downgrades

Stocks Mentioned

BRLI 33.58

+0.88 +2.69%
Volume: 29,206
Track BRLI


Add Your Comment